Cryopyrin Associated Periodic Syndrome
8
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
11 treatments under study, led by Questionnaire
Research Leaders
9 sponsors active, led by Novartis Pharmaceuticals
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (8)
Circadian Rhythm Deregulation in Patients With CAPS
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
Adult Outcomes of Children With CAPS
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
Are Mast Cells Involved in Autoinflammatory Diseases
Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimer’s disease and Parkinson’s disease.
Research Network
Common Treatments
- Questionnaire1
- Vtx27351
- Blood Sampling1
- Izd3341
- Placebos1
Active Sponsors
- Novartis Pharmaceuticals1
- University Hospital, Lille1
- NodThera Limited1
- Zydus Lifesciences Limited1
- Zomagen Biosciences Ltd.1
Top Investigators
University Hospital, Lille
Nucleus Network
Ventyx Biosciences, Inc
Cadila Healthcare Ltd.
Assistance Publique - Hôpitaux de Paris
Related Conditions
- Mkd1
- Traps1
- Mucklewells Syndrome1
- Autoinflammatory Disease1
- Fmf1